视网膜静脉阻塞性黄斑水肿药物治疗后的眼屈光度改变

发布时间：2018-06-11 20:35

本文选题：屈光度改变 + 黄斑水肿　；参考：《眼科》2017年01期

【摘要】：目的探讨视网膜静脉阻塞性黄斑水肿经药物治疗消退后的屈光度改变。设计回顾性病例系列。研究对象46例46眼视网膜静脉阻塞性黄斑水肿患者,初诊时无黄斑脱离组19眼及伴有黄斑脱离组27眼。方法患者经玻璃体腔注射抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物(康柏西普或雷珠单抗)或后筋膜下注射曲安奈德(triamcinolone,TA)后,黄斑水肿消退或近乎消退定义为终末随诊点。分析两组基线与终末随诊的等效球镜度(spherical equivalent refraction,SE)差异。主要指标SE。结果基线不伴有黄斑脱离组,基线时SE(0.38±1.71)D,终末随诊点SE(0.32±1.68)D,SE差值绝对值平均值(0.31±0.32)D,SE改变无统计学意义(t=0.577,P=0.571)。基线伴有黄斑脱离组,基线时SE(0.79±1.25)D,终末随诊点SE(0.26±1.15)D,SE差值绝对值平均值(0.88±0.81)D,SE改变有统计学意义(t=2.541,P=0.017)。结论对于不伴有黄斑脱离的视网膜静脉阻塞性黄斑水肿患者不必延迟屈光矫正。
[Abstract]:Objective to investigate the diopter changes of retinal vein obstructive macular edema after drug treatment. A retrospective case series was designed. 46 cases of retinal vein obstructive macular edema in 46 eyes were studied, 19 eyes without macular detachment and 27 eyes with macular detachment in the first diagnosis. Methods patients were injected with vascular endothelia via intravitreal injection. Naga Innoko (vascular endothelial growth factor, VEGF) drugs (compaccp or rezumumab) or subfascial injection of Cu Ann Ned (triamcinolone, TA), macular edema decline or near extinction defined as terminal follow-up point. Analysis of the two groups of baseline and terminal follow-up of the difference in the degree of equal efficacy (spherical equivalent refraction, SE). The baseline of SE. was not accompanied by macular detachment, SE (0.38 + 1.71) D at baseline, SE (0.32 + 1.68) D, and SE difference absolute value (0.31 + 0.32) D, SE was not statistically significant (t=0.577, P=0.571). The baseline was accompanied by macular detachment, SE (0.79 + 1.25) D, the end of the baseline (0.26 + 1.15), and the mean value of the absolute value of the difference (0.. 88 + 0.81) D, SE changes were statistically significant (t=2.541, P=0.017). Conclusion there is no delay in refractive correction for patients with retinal vein obstructive macular edema without macular detachment.
【作者单位】：温州医科大学附属眼视光医院;
【基金】：国家重大新药创制专项课题“眼视光药物临床试验技术平台”(2014ZX09303301) 浙江省重大科技专项重大社会发展项目(2013C03048-3) 温州市科技计划项目(Y20150284)
【分类号】：R774

【参考文献】